Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rayson, D.
Right arrow Articles by Ingle, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rayson, D.
Right arrow Articles by Ingle, J. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:413-419, 1999
© 1999 European Society for Medical Oncology

research-article

Metaplastic breast cancer: Prognosis and response to systemic therapy

D. Rayson1,4, A. A. Adjei1,, V. J. Suman2, L. E. Wold3 and J. N. Ingle1

1Division of Medical Oncology Rochester. MN, USA
2Section ofBiostatistics Rochester. MN, USA
3Laboratory Medicine and Pathology. Mayo Clinic and Foundation Rochester. MN, USA
4Current address: London Regional Cancer Center London, Ontario, Canada

Correspondence to: A. A. Adjei, MD, Division of Medical Oncology, Mayo Clinic, 200 First St. S.W., Rochester, MN 55905, USA. E-mail: adjei.alex{at}mayo.edu

Background: Metaplastic breast cancer is a rare disease with little information available to guide therapy. The goals of this study were to describe the patient characteristics, systemic therapies and clinical outcomes of all patients with primary metaplastic breast cancer treated at Mayo Clinic between 1976 and 1997.

Patients and methods: Patients were identified through the medical index of Mayo Clinic. Clinical information was abstracted from the medical record of each patient. A literature search using MEDLINE and CANCERLIT for the years 1966-1997 was performed to identify all previously reported case series in the English language containing 10 or more patients.

Results: Twenty-seven patients were identified with a median age at diagnosis of 59 years (range 39–90 years). The median tumor size was 3.4 cm (range 0.5–7.0 cm). One patient had metastatic disease at presentation. Twenty-three patients had information available on nodal status, estrogen receptor (ER) and progesterone receptor (PR) status. Twenty patients (87%) were node-negative and three patients (13%) were both ER and PR positive. Disease-free survival (DFS) and overall survival (OS) were assessed for those who presented with local-regional disease. The three-year DFS was 40% (95% CI: 23%-73%) and the three-year OS was 71% (95% CI: 51%-97%). In univariate analysis, those patients 60 years of age or older at diagnosis were found to have an increased DFS (P = 0.011). Among those with prior estrogen use, both DFS (P = 0.022) and OS (P = 0.003) were decreased. Thirteen patients (50%) developed metastases with a median DFS time of 2.4 years. Ten different chemotherapy regimens were utilized for metastatic disease and one partial response was observed. There were no responses to tamoxifen in four patients with metastatic disease. Median survival after the development of metastases was eight months.

Conclusions: Despite presenting more commonly as node-negative disease, DFS and OS in metaplastic breast cancer is decreased compared to typical adenocarcinomas. Systemic therapy also appears to be less effective. Patients with metaplastic breast cancer, particularly those with metastatic disease could be appropriate candidates for innovative therapeutic regimens.

metaplastic breast cancer, prognosis, systemic therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K.-H. Lim, D.-Y. Oh, E. K. Chie, W. Han, S.-A. Im, T.-Y. Kim, I. A. Park, D.-Y. Noh, S. W. Ha, and Y.-J. Bang
Metaplastic Breast Carcinoma: Clinicopathologic Features and Prognostic Value of Triple Negativity
Jpn. J. Clin. Oncol., November 3, 2009; (2009) hyp139v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. A. Gilbert, M. P. Goetz, C. A. Reynolds, J. N. Ingle, K. F. Giordano, V. J. Suman, H. E. Blair, R. B. Jenkins, W. L. Lingle, M. M. Reinholz, et al.
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy
Mol. Cancer Ther., April 1, 2008; 7(4): 944 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
W. T. Yang, B. Hennessy, K. Broglio, C. Mills, N. Sneige, W. G. Davis, V. Valero, K. K. Hunt, and M. Z. Gilcrease
Imaging Differences in Metaplastic and Invasive Ductal Carcinomas of the Breast
Am. J. Roentgenol., December 1, 2007; 189(6): 1288 - 1293.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
V. Bossuyt, O. Fadare, M. Martel, I. T. Ocal, B. Burtness, F. Moinfar, S. Leibl, and F. A. Tavassoli
Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation
International Journal of Surgical Pathology, October 1, 2005; 13(4): 319 - 327.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.